Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study

Objective : Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A pivotal double-blind (DB) study of children aged 6–12 years with ADHD demonstrated efficacy for ADHD with good tolerability...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of child and adolescent psychopharmacology 2023-03, Vol.33 (2), p.51-58
Hauptverfasser:	Childress, Ann C, Marraffino, Andrea, Cutler, Andrew J, Oh, Charles, Brams, Matthew N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Appetite loss Attention Deficit Disorder with Hyperactivity - drug therapy Attention deficit hyperactivity disorder Blood pressure Central Nervous System Stimulants - adverse effects Child Children Classrooms Clinical trials Delayed-Action Preparations Dexmethylphenidate Hydrochloride - adverse effects Dose-Response Relationship, Drug Double-Blind Method Humans Hyperactivity Insomnia Medical laboratories Methylphenidate Methylphenidate - adverse effects Original Population studies Respiratory tract diseases Rhinopharyngitis Safety Sleep Treatment Outcome Vital signs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!